Why Urea Helps in Hyponatremia
Urea helps in hyponatremia by inducing an osmotic diuresis that promotes free water excretion without causing significant electrolyte losses, making it particularly effective for treating SIADH (syndrome of inappropriate antidiuretic hormone secretion) and other forms of euvolemic/hypervolemic hyponatremia.
Mechanism of Action
Urea works through a fundamentally different pathway than traditional treatments:
- Osmotic diuresis: Urea increases urinary water excretion by creating an osmotic gradient in the renal tubules, allowing the kidneys to eliminate excess free water while preserving sodium 1, 2
- Reduces sodium wasting: Unlike fluid restriction alone, urea actually decreases urinary sodium excretion when hyponatremia is significant (serum sodium <130 mEq/L), helping to correct the "salt-losing" tendency seen in SIADH 1
- Allows normal fluid intake: By promoting water excretion, urea permits patients to maintain adequate hydration (>2L/day) despite ongoing inappropriate ADH secretion, which is a major advantage over fluid restriction 2
Clinical Evidence for Efficacy
The research evidence strongly supports urea's effectiveness:
In SIADH specifically: A 2024 meta-analysis demonstrated that urea significantly increases serum sodium (mean difference 9.08 mEq/L, P<0.01) across all severities of hyponatremia 3. The effect is even more pronounced in severe cases (<120 mEq/L), with increases of 18.04 mEq/L compared to 7.86 mEq/L in moderate cases 3.
Comparative effectiveness: Urea performs comparably to vaptans (mean difference -1.96 mEq/L, P=0.1) and fluid restriction (mean difference 0.81 mEq/L, P=0.4), but is superior to no treatment 3. A 2025 real-world study found that 61.7% of patients on urea achieved normal sodium levels, similar to the 63.2% with tolvaptan, though tolvaptan worked faster (21 days vs 42 days) 4.
Time course: Urea works across multiple timeframes - significant increases occur within 24 hours in acute settings 2, with continued improvement at 2,5,7, and 14 days, and sustained efficacy up to 1 year 3.
Clinical Context and Limitations
Important caveat: The guidelines provided focus primarily on cirrhosis-related hyponatremia, where the evidence base is different. In cirrhosis with hypervolemic hyponatremia, current guidelines do not recommend urea as a standard treatment 5, 6. The 2021 Gut guidelines note that vaptans improve sodium levels in cirrhosis but are not routinely recommended due to increased mortality (31% vs 22%) and hepatotoxicity 6.
However, for SIADH and euvolemic hyponatremia (the most common context where urea is used), the research evidence is compelling. A 2010 ICU study showed urea corrected mild hyponatremia from 128 to 135 mEq/L within 2 days, and severe hyponatremia from 111 to 122 mEq/L within 24 hours 2.
Practical Advantages
- Safety profile: No cases of osmotic demyelination syndrome have been reported with urea, though hypernatremia can occur (monitor sodium levels) 2, 3
- Cost-effectiveness: Significantly less expensive than vaptans 7, 8
- Tolerability: Main side effect is poor palatability, though flavored formulations now address this 8, 9. Minor adverse events are uncommon 3
- Dosing: Typical doses range from 30-60g/day (0.5-1 g/kg/day), administered orally or via nasogastric tube 2, 3
Common Pitfall
The major pitfall is underutilization due to lack of clinician familiarity 8. Despite decades of evidence showing efficacy, urea remains overlooked in North America, particularly compared to more expensive vaptans that carry hepatotoxicity risks. The 2009 neurosurgical guidelines mention urea as an effective treatment for SIADH 10, but it has not been widely adopted into mainstream practice algorithms.
Bottom line: For SIADH-induced hyponatremia, urea is an effective, safe, and underutilized option that works by promoting selective water excretion while preserving sodium, offering a practical alternative when fluid restriction fails or vaptans are contraindicated.